Select Publications
Journal articles
2023, '“It's like a forgotten issue sometimes …”: Qualitative study of individuals living and caring for people with chronic breathlessness', Clinical Respiratory Journal, 17, pp. 694 - 700, http://dx.doi.org/10.1111/crj.13652
,2023, 'Management of chronic breathlessness in primary care: what do GPs, non-GP specialists, and allied health professionals think?', Australian Journal of Primary Health, 29, pp. 375 - 384, http://dx.doi.org/10.1071/py22018
,2022, 'Assessment and diagnosis of chronic dyspnoea: a literature review', npj Primary Care Respiratory Medicine, 32, http://dx.doi.org/10.1038/s41533-022-00271-1
,2022, 'Systematic review of effectiveness and quality assessment of patient education materials and decision aids for breathlessness', BMC Pulmonary Medicine, 22, http://dx.doi.org/10.1186/s12890-022-02032-9
,2022, 'Dual bronchodilator treatment for prevention of COPD in at-risk smokers', Respirology, 27, pp. 983 - 986, http://dx.doi.org/10.1111/resp.14357
,2022, 'Efficacy of self-management mobile applications for patients with breathlessness: Systematic review and quality assessment of publicly available applications', Respiratory Medicine, 201, http://dx.doi.org/10.1016/j.rmed.2022.106947
,2022, 'Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCS Trial', International Journal of COPD, 17, pp. 273 - 282, http://dx.doi.org/10.2147/COPD.S339889
,2021, 'Clinical researchers’ lived experiences with data quality monitoring in clinical trials: a qualitative study', BMC Medical Research Methodology, 21, http://dx.doi.org/10.1186/s12874-021-01385-9
,2021, 'Preventing adverse cardiac events (PACE) in chronic obstructive pulmonary disease (COPD): Study protocol for a double-blind, placebo controlled, randomised controlled trial of bisoprolol in COPD', BMJ Open, 11, http://dx.doi.org/10.1136/bmjopen-2021-053446
,2021, 'The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: The TASCS randomised controlled trial', European Respiratory Journal, 57, http://dx.doi.org/10.1183/13993003.03338-2020
,2021, 'Time-consuming and expensive data quality monitoring procedures persist in clinical trials: A national survey', Contemporary Clinical Trials, 103, http://dx.doi.org/10.1016/j.cct.2021.106290
,2020, 'Heterogeneity in clinical research data quality monitoring: A national survey', Journal of Biomedical Informatics, 108, http://dx.doi.org/10.1016/j.jbi.2020.103491
,2019, 'The clinical utility of the AUSDRISK tool in assessing change in type 2 diabetes risk in overweight/obese volunteers undertaking a healthy lifestyle intervention', Preventive Medicine Reports, 13, pp. 80 - 84, http://dx.doi.org/10.1016/j.pmedr.2018.11.020
,2018, 'Assessing data quality and the variability of source data verification auditing methods in clinical research settings', Journal of Biomedical Informatics, 83, pp. 25 - 32, http://dx.doi.org/10.1016/j.jbi.2018.05.010
,2018, 'Exploring data quality management within clinical trials', Applied Clinical Informatics, 9, pp. 72 - 81, http://dx.doi.org/10.1055/s-0037-1621702
,2018, 'Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial', Antiviral Therapy, 23, pp. 21 - 32, http://dx.doi.org/10.3851/IMP3171
,2017, 'A systematic method to evaluate the dietary intake data coding process used in the research setting', Journal of Food Composition and Analysis, 64, pp. 27 - 32, http://dx.doi.org/10.1016/j.jfca.2017.07.010
,2017, 'Effect of interdisciplinary care on weight loss: A randomised controlled trial', BMJ Open, 7, http://dx.doi.org/10.1136/bmjopen-2016-014533
,2017, 'Data mining: Potential applications in research on nutrition and health', Nutrition and Dietetics, 74, pp. 3 - 10, http://dx.doi.org/10.1111/1747-0080.12337
,2017, 'Impact of providing walnut samples in a lifestyle intervention for weight loss: A secondary analysis of the HealthTrack trial', Food and Nutrition Research, 61, http://dx.doi.org/10.1080/16546628.2017.1344522
,2016, 'Identifying metabolic syndrome in a clinical cohort: Implications for prevention of chronic disease', Preventive Medicine Reports, 4, pp. 502 - 506, http://dx.doi.org/10.1016/j.pmedr.2016.09.007
,2016, 'Feasibility of a community-based interdisciplinary lifestyle intervention trial on weight loss (the HealthTrack study)', Nutrition and Dietetics, 73, pp. 321 - 328, http://dx.doi.org/10.1111/1747-0080.12234
,2015, 'Interdisciplinary lifestyle intervention for weight management in a community population (HealthTrack study): Study design and baseline sample characteristics', Contemporary Clinical Trials, 45, pp. 394 - 403, http://dx.doi.org/10.1016/j.cct.2015.10.008
,2015, 'Measuring Data Quality Through a Source Data Verification Audit in a Clinical Research Setting', Studies in Health Technology and Informatics, 214, pp. 107 - 113, http://dx.doi.org/10.3233/978-1-61499-558-6-107
,2013, 'Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy', AIDS, 27, pp. 2403 - 2411, http://dx.doi.org/10.1097/01.aids.0000432534.47217.b4
,2013, 'HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.', PloS one, 8, http://dx.doi.org/10.1371/journal.pone.0077138
,2013, 'Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, open-label, non-inferiority study', Lancet, 381, pp. 2091 - 2099, http://dx.doi.org/10.1016/S0140-6736(13)61164-2
,2012, 'The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.', AIDS, 26, pp. 2337 - 2344, http://dx.doi.org/10.1097/QAD.0b013e32835ab213
,2011, 'Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or Abacavir-Lamivudine', PLoS One, 6, pp. Article number e26885, http://dx.doi.org/10.1371/journal.pone.0026885
,2010, 'Reply to Landman and Soonawala', Clinical Infectious Diseases, 50, pp. 1200 - 1201, http://dx.doi.org/10.1086/651469
,2010, 'Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial', AIDS, 24, pp. 2657 - 2663
,2010, 'Simplification with fixed-dose tenofovir-emtricitabine or abacavir-lamivudine in treatment experienced, virologically suppressed adults with HIV infection: combined analysis of two randomised, non-inferiority trials Bicombo and Steal.', Journal of AIDS & Clinical Research, 1, pp. 1001 - 1013, http://dx.doi.org/10.4172/2155-6113.1000103
,2009, 'Adiponectin isoform distribution in women-relationship to femal sex steroids and insulin sensitivity', Metabolism - Clinical and Experimental, 58, pp. 239 - 245
,2009, 'Metabolic disorders and cardiovascular consequences of HIV infection and antiretroviral therapy', Expert Review of Clinical Pharmacology, 2, pp. 381 - 390
,2009, 'Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial', Clinical Infectious Diseases, 49, pp. 1591 - 1601
,2006, 'Serum Adiponectin Levels in Normal and Hypertensive Pregnancy', Hypertension in Pregnancy, 25, pp. 193 - 203
,2005, 'Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial', AIDS, 19, pp. 1325 - 1327
,2005, 'Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy', Antiviral Therapy, 10, pp. 135 - 143
,2005, 'Therapeutic approaches to combating lipoatrophy: do they work?', Journal of Antimicrobial Chemotherapy, 55, pp. 612 - 615
,2004, 'No effect of rosiglitazone for treatment of HIV-1 lipoatrophy:randomised, double-blind, placebo-controlled trial', Lancet, 363, pp. 429 - 438, http://dx.doi.org/10.1016/S0140-6736(04)15489-5
,2004, 'Progression of lipodystrophy (LD) with continued thymidine analogue usage: Long-term follow-up from a randomized clinical trial (the PIILR study)', HIV Clinical Trials, 5, pp. 192 - 200, http://thomasland.metapress.com/content/0gu76x27mmhe5ale/
,2004, 'Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study', AIDS, 18, pp. 1029 - 1036, http://www.medscape.com/viewarticle/474870
,2004, 'Rosiglitazone for HIV lipoatrophy: 84 weeks follow-up', Antiviral Therapy, 9, pp. L46 - L46
,2003, 'Centralised assessment of dual-energy x-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy', HIV Clinical Trials, 4, pp. 45 - 49
,2003, 'Thymidine analogue withdrawal for patients on protease sparing therapy improves lipoatrophy but compromises antivrial control:the PIILR extension study', AIDS, 16, pp. 2489 - 2491, http://journals.lww.com/aidsonline/fulltext/2002/12060/thymidine_analogue_withdrawal_for_lipoatrophic.20.aspx
,2002, 'Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy', JAMA - Journal of the American Medical Association, 288, pp. 207 - 215
,2001, 'Is resistant hypertension really resistant?', American Journal of Hypertension, 14, pp. 1263 - 1269, http://dx.doi.org/10.1016/S0895-7061(01)02193-8
,2001, 'Effects of oral L-arginine on plasma nitrate and blood pressure in cortisol-treated humans', Journal of Hypertension, 19, pp. 263 - 268, http://dx.doi.org/10.1097/00004872-200102000-00013
,2001, 'Body composition an energy metabolism in normotensive and hypertensive pregnancy', British Journal of Obstetrics and Gynaecology, 108, pp. 1263 - 1271
,2001, 'Body composition and energy metabolism in normotensive and hypertensive pregnancy', BJOG: An International Journal of Obstetrics & Gynaecology, 108, pp. 1263 - 1271, http://dx.doi.org/10.1111/j.1471-0528.2001.00289.x
,